Free Trial
OTCMKTS:IPCIF

Intellipharmaceutics International (IPCIF) Stock Price, News & Analysis

Intellipharmaceutics International logo

About Intellipharmaceutics International Stock (OTCMKTS:IPCIF)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
12,042 shs
Market Capitalization
$4.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Intellipharmaceutics International Inc. was a Canadian specialty pharmaceutical company focused on developing and commercializing oral, controlled-release drug products. Its work centered on proprietary drug-delivery technologies designed to regulate the release of active pharmaceutical ingredients and support the development of extended-release and abuse-deterrent formulations.

The company pursued both generic and novel prescription medicines, including extended-release versions of established drugs and its Rexista oxycodone product, an abuse-deterrent formulation developed for the treatment of pain. Intellipharmaceutics also sought regulatory approvals and commercial partnerships in the United States and Canada for selected products and product candidates.

Founded in 1998 and based in Toronto, Ontario, Intellipharmaceutics was historically led by co-founder Dr. Isa Odidi. The company’s business activities were primarily directed toward pharmaceutical research, formulation development, regulatory submissions and licensing or partnering opportunities rather than operating a broad consumer-facing healthcare business.

AI Generated. May Contain Errors.

Receive IPCIF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellipharmaceutics International and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IPCIF Stock News Headlines

My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
See More Headlines

IPCIF Stock Analysis - Frequently Asked Questions

Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) issued its quarterly earnings results on Monday, July, 16th. The company reported ($0.70) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.70). The firm had revenue of $580 thousand for the quarter, compared to the consensus estimate of $900 thousand.

Intellipharmaceutics International's stock reverse split on the morning of Friday, September 14th 2018.The 1-10 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Intellipharmaceutics International investors own include Micron Technology (MU), Eyepoint Pharmaceuticals (EYPT), Aurinia Pharmaceuticals (AUPH), Anavex Life Sciences (AVXL), Protalix BioTherapeutics (PLX), Chesapeake Energy (CHKAQ) and BioLineRx (BLRX).

Company Calendar

Today
11/14/2026
Fiscal Year End
11/30/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:IPCIF
CIK
1474835
Employees
10
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$660 thousand
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.32) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
33,093,000
Free Float
32,511,000
Market Cap
$4.96 million
Optionable
Not Optionable
Beta
1.53
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (OTCMKTS:IPCIF) was last updated on 11/6/2026 by MarketBeat.com Staff.
From Our Partners